Harnessing the Immunological Effects of Radiation to Improve Immunotherapies in Cancer.

Harnessing the Immunological Effects of Radiation to Improve Immunotherapies in Cancer.
复制标题

利用辐射的免疫效应改善癌症免疫疗法。

DOI:
10.3390/ijms24087359
复制
发表时间:
2023-04-16
影响因子:
5.6
通讯作者:
Gerber, Scott A.
Gerber, Scott A.
中科院分区:
生物学2区
文献类型:
--
作者:
Hannon, Gary;Lesch, Maggie L.;Gerber, Scott A.

文献摘要

参考文献

相似文献

电离辐射(IR)用于治疗50%的癌症。虽然自20世纪初以来,人们就已经知道了与IR引起的DNA损伤相关的细胞毒性作用,但免疫系统在治疗反应中的作用仍有待完全确定。IR可以诱导免疫原性细胞死亡(ICD),从而激活针对癌症的先天和适应性免疫。它也被广泛报道,一个完整的免疫系统是必不可少的IR疗效。然而,这种反应通常是短暂的,伤口愈合过程也变得上调,抑制了早期克服疾病的免疫努力。这种免疫抑制涉及许多复杂的细胞和分子机制,最终导致在许多情况下产生辐射抗性。了解这些反应背后的机制是具有挑战性的,因为这些影响是广泛的,并且经常在肿瘤内同时发生。在这里,我们描述了IR对肿瘤免疫景观的影响。我们将讨论ICD以及骨髓和淋巴细胞对IR的反应,希望能阐明这种基础癌症治疗中涉及的复杂免疫刺激和免疫抑制反应。利用这些免疫效应可以为未来提高免疫治疗效果提供一个平台。
Ionizing radiation (IR) is used to treat 50% of cancers. While the cytotoxic effects related to DNA damage with IR have been known since the early 20th century, the role of the immune system in the treatment response is still yet to be fully determined. IR can induce immunogenic cell death (ICD), which activates innate and adaptive immunity against the cancer. It has also been widely reported that an intact immune system is essential to IR efficacy. However, this response is typically transient, and wound healing processes also become upregulated, dampening early immunological efforts to overcome the disease. This immune suppression involves many complex cellular and molecular mechanisms that ultimately result in the generation of radioresistance in many cases. Understanding the mechanisms behind these responses is challenging as the effects are extensive and often occur simultaneously within the tumor. Here, we describe the effects of IR on the immune landscape of tumors. ICD, along with myeloid and lymphoid responses to IR, are discussed, with the hope of shedding light on the complex immune stimulatory and immunosuppressive responses involved with this cornerstone cancer treatment. Leveraging these immunological effects can provide a platform for improving immunotherapy efficacy in the future.
DOI: 10.3389/fonc.2018.00322
发表时间: 2018
影响因子: 4.7
作者:
Budhwani M;Mazzieri R;Dolcetti R
通讯作者: Dolcetti R
DOI: 10.1158/0008-5472.can-10-2820
发表时间: 2011-04-01
期刊: Cancer research
影响因子: 11.2
作者:
Burnette BC;Liang H;Lee Y;Chlewicki L;Khodarev NN;Weichselbaum RR;Fu YX;Auh SL
通讯作者: Auh SL
DOI: 10.1038/s41419-020-03209-y
发表时间: 2020-11-23
影响因子: 9
作者:
Adjemian S;Oltean T;Martens S;Wiernicki B;Goossens V;Vanden Berghe T;Cappe B;Ladik M;Riquet FB;Heyndrickx L;Bridelance J;Vuylsteke M;Vandecasteele K;Vandenabeele P
通讯作者: Vandenabeele P
DOI: 10.1038/nrc1451
发表时间: 2004-09-01
影响因子: 78.5
作者:
Bernier, J;Hall, EJ;Giaccia, A
通讯作者: Giaccia, A
DOI: 10.1016/s1074-7613(01)00111-x
发表时间: 2001-03-01
期刊: IMMUNITY
影响因子: 32.4
作者:
Basu, S;Binder, RJ;Srivastava, PK
通讯作者: Srivastava, PK